Search company, investor...

ActivBiotics

activbiotics.com

Founded Year

1996

Stage

Dead | Dead

Total Raised

$36.74M

About ActivBiotics

ActivBiotics is focused on the development and commercialization of antibacterials for the treatment of acute and chronic disease. The Company is developing rifalazil - a potent broad spectrum antibiotic that targets and inhibits the transcriptional machinery of bacteria.

Headquarters Location

110 Hartwell Avenue

Lexington, Massachusetts, 02421,

United States

781-372-4800

Missing: ActivBiotics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: ActivBiotics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

ActivBiotics Patents

ActivBiotics has filed 4 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/23/2004

10/26/2010

Inflammations, Bacterial diseases, Antibiotics, Infectious diseases

Grant

Application Date

9/23/2004

Grant Date

10/26/2010

Title

Related Topics

Inflammations, Bacterial diseases, Antibiotics, Infectious diseases

Status

Grant

Latest ActivBiotics News

PRESS RELEASE: ActivBiotics Sells Proprietary Assets, Including Drug Product Candidates

Feb 2, 2018

Dec 19, 2007 1:21pm ActivBiotics Sells Proprietary Assets, Including Drug Product Candidates LEXINGTON, MA, December 18, 2007 -- ActivBiotics, Inc. today announced that following a review of strategic options after its clinical trial of Rifalazil failed in peripheral arterial disease patients, the Company is selling all or substantially all of its assets on an “as is” basis through an Assignment for the Benefit of Creditors, process.  The Assignee of the assets is Mr. Joseph Finn, Jr., CPA (see contact details below).  The bidding for the assets, which may be purchased separately or in combination, will begin today and end on February 1, 2008.  Any person interested in purchasing the assets or learning more about the bidding process should contact the Assignee, Mr. Joseph Finn, Jr. “The Board of Directors has decided to pursue the sale of the company’s clinical and preclinical drug assets”, said Steven C. Gilman, Ph.D., Chairman of ActivBiotics. “We believe that our anti-inflammatory Phase II drug candidate and our antibacterial library of compounds are of significant value to companies in those therapeutic areas,” added Gilman.  Bidding packages have been assembled and are ready to be distributed subject to a potential purchaser entering into a standard form confidentiality agreement. The Company assets available for sale include: 1.  A superoxide dismutase (SOD) mimetic program consisting of two clinical-stage drug candidates, M40403 and M40419, and a library of 250 small molecules which have potential as novel therapeutic agents for the treatment of inflammatory diseases.  M40403, which has been studied in approximately 700 patients/subjects, has an active IND, and a protocol on file with the FDA under which a Phase II clinical trial for the treatment of post-operative ileus can be conducted, and a protocol to initiate a Phase II clinical trial for the treatment of oral mucositis.  The Company has submitted and expects to shortly receive Orphan Drug Designation status in Europe and has an Orphan Drug application pending with the US FDA for the treatment of oral mucositis in subjects with advanced head and neck cancer.  In addition to these indications, the SOD mimetics have potential therapeutic uses in a variety of inflammatory disorders including asthma, chronic obstructive pulmonary disease, and radiation protection, stroke, and ischemia reperfusion injury. 2.  An antibacterial library of compounds consisting of approximately 800 small molecules, all new chemical entities (NCEs), which may be developed for the treatment of serious bacterial infections, including complicated skin and skin structure infections, endocarditis, osteomyelitis, foreign-body infections, Clostridium difficile-associated diarrhea (CDAD), as well as peptic ulcer disease due to Helicobacter pylori, and disease due to Chlamydia infections. In addition, these NCEs have the potential to be administered as topical agents for the treatment of acne and for the eradication of Staphylococcus aureus in nasal passages. 3.  Rifalazil, a clinical stage compound which has been tested in approximately 600 patients, is a potent antibacterial agent with activity mainly against pathogenic Gram-positive bacteria.  Rifalazil was found efficacious in a Phase II Chlamydia STD clinical trial, and, separately, a protocol has been submitted to the FDA to begin a Phase II clinical trial in carotid artery atherosclerosis. Rifalazil has been granted Fast Track designation for the treatment of CDAD. The Company has open INDs to continue rifalazil development for infectious diseases, and atherosclerosis-related disease. Request for Further Information Interested parties can obtain a bidder’s package by contacting Joseph F. Finn, Jr., CPA ( [email protected] , phone 781-237-8840), Finn, Warnke & Gayton, 167 Worcester Street, Suite 201, Wellesley Hills, MA  02481-3613. The package is intended to provide prospective purchasers with information concerning the Company’s Sale of Assets and conveyancing documents.  For technical information or questions regarding the products all such inquiries shall be directed to Christo Shalish, [email protected] , and/or Glenn Kazo, [email protected] .  Safe Harbor Statement This press release may contain or incorporate by reference certain statements that are not historical facts, including statements preceded by, followed by or that include the words “may,” “believes,” “will”, “expects,” “anticipates” or the negation thereof, or similar expressions, which constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements that address events, transactions or developments that are expected or anticipated to occur in the future are forward-looking statements within the meaning of the Reform Act. Such forward-looking statements involve risks, uncertainties and other factors that may cause the actual performance or achievements of ActivBiotics, Inc. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. For those statements, ActivBiotics, Inc. claims the protection of the safe harbor for forward-looking statements contained in the Reform Act.  ActivBiotics, Inc. will not undertake and specifically declines any obligation to publicly release the result of any revisions that may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events. About the Author

ActivBiotics Frequently Asked Questions (FAQ)

  • When was ActivBiotics founded?

    ActivBiotics was founded in 1996.

  • Where is ActivBiotics's headquarters?

    ActivBiotics's headquarters is located at 110 Hartwell Avenue, Lexington.

  • What is ActivBiotics's latest funding round?

    ActivBiotics's latest funding round is Dead.

  • How much did ActivBiotics raise?

    ActivBiotics raised a total of $36.74M.

  • Who are the investors of ActivBiotics?

    Investors of ActivBiotics include BioVentures Investors, Delphi Ventures, Lumira Ventures, Vanderbilt University and New England Partners.

  • Who are ActivBiotics's competitors?

    Competitors of ActivBiotics include Aquinox Pharmaceuticals, Intarcia Therapeutics, Nabriva Therapeutics, Affinium Pharmaceuticals, KAI Pharmaceuticals and 9 more.

Compare ActivBiotics to Competitors

I
Inimex Pharmaceuticals

Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. nnAdditional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.

O
Oculus Innovative Sciences

Oculus Innovative Sciences develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform features a biocompatible, shelf-stable solution containing active oxychlorine compounds that is currently commercialized in the United States, Europe, India, China and Mexico for the treatment of infected wounds. The solutions derived from this platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores. The company's headquarters are in Petaluma, California, with operations in Europe and Latin America.

CoImmune Logo
CoImmune

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

U
Ulysses Pharmaceuticals

Ulysses Pharmaceuticals is dedicated to the discovery and development of safe antimicrobial agents for the treatment of severe and recurrent infections occurring in humans. The Company intends to become an industry leader in the antiinfective field through the development of new antibiotics including some acting as Trojan Horses that take advantage of essential microbial transport systems to specifically enter targeted pathogens. Ulysses concentrates on the development of advanced hit and lead compounds with promising features and characteristics that are indicative of potent antibacterial agents with potential for strong market penetration.

C
Catena Pharmaceuticals

Catena Pharmaceuticals is focused on the development and commercialization of GPCR antagonists, particularly in the areas of cancer and fibrotic disease. Catena's chemistry is capable of affecting a specific class of GPCRs known to be relevant in a variety of disease states.

L
Locus Pharmaceuticals

Locus Pharmaceuticals is a privately held pharmaceutical company focused on developing small molecule therapeutic drugs to address unmet medical needs. The company's core technology is a fragment-based, computational approach, which Locus has combinated with highly integrated medicinal chemistry, crystallography and biology capabilities to create a unique drug design and development platform.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.